TIL for Cancer
Trial Summary
What is the purpose of this trial?
This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist. Study details include: * The study will last up to 2 years after the TIL infusion (Day 0) for each person. * The treatment will last up to 10 days for each person. * Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.
Do I have to stop taking my current medications for the TIL for Cancer trial?
The trial information does not specify if you need to stop taking your current medications. However, if you are on systemic steroid therapy higher than the physiologic replacement dose, you may not be eligible to participate.
Research Team
Iovance Biotherapeutics Study Team
Principal Investigator
Iovance Biotherapeutics
Eligibility Criteria
This trial is for young individuals with certain types of cancer (like Ewing Sarcoma, various sarcomas, brain cancer, and melanoma) that have come back or aren't responding to treatment. It's specifically for those without effective standard treatments available.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the TIL regimen for up to 10 days
Initial Follow-up
Participants are monitored every 2 weeks until Day 42 for safety and effectiveness
Extended Follow-up
Participants are monitored every 6 weeks until Month 6, then every 3 months until Year 2
Treatment Details
Interventions
- LN-145/LN-144 (CAR T-cell Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Iovance Biotherapeutics, Inc.
Lead Sponsor